［1］中华医学会感染病学分会肝衰竭与人工肝学组.中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南［J］.中华肝脏病杂志，2013，21(3)：177-183.［2］王宇明，汤影子.重型乙型肝炎发病机制研究进展［J］.传染病信息，2008，21(2)：68-70，94.［3］Deng G，Zhou G，Zhang R，et al.Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers［J］.Gastroenterology，2008，134(3)：716-726.［4］Morley M，Molony CM，Weber TM，et al.Genetic analysis of genome-wide variation in human gene expression［J］.Nature，2004，430(71)：743-747.［5］Ge H，Wei M，Fabrizio P，et al.Comparative analyses of time-course gene expression profiles of the long-lived sch9Delta mutant［J］.Nucleic Acids Res，2010，38(1)：143-158.［6］Sarin SK，Kumar A，Almeida JA，et al.Acute-on-chronic liver failure：consensus recommendations of the Asian Pacific Association for the Study ofthe Liver(APASL)［J］.Hepatol Int，2009，3(2)：269-282.［7］Wang YM，Tang YZ.Antiviral therapy for hepatitis B virus associated hepatic failure［J］.Hepatobiliary Pancreat Dis Int，2009，8(1)：17-24.［8］Lange CM，Bojunga J，Hofmann WP，et al.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function［J］.Hepatology，2009，50(6)：2001-2006.［9］Keating GM.Entecavir：a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease［J］.Drugs，2011，71(18)：2511-2529.［10］Kim YJ，Sinn DH，Gwak GY，et al.Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures［J］.World J Gastroenterol，2012，18(47)：6996-7002.［11］Garg H，Sarin SK，Kumar M，et al.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure［J］.Hepatology，2011，53(3)：774-780.［12］Liaw YF，Sheen IS，Lee CM，et al.Tenofovir disoproxil fumarate (TDF)，emtricitabine/TDF，and entecavir in patients with decompensated chronic hepatitis B liver disease［J］.Hepatology，2011，53(1)：62-72.［13］Sarri G，Westby M，Bermingham S，et al.Diagnosis and management of chronic hepatitis B in children，young People，and adults：summary of Nice guidance［Z］，2013：f3893.［14］Fung SK，Lok AS.Management of patients with hepatitis B virus-induced cirrhosis［J］.J Hepatol，2005，42(1，Supplement)：S54-S64.［15］Park H，Park JY，Kim SU，et al.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir［J］.World J Gastroenterol，2013，19(43)：7671-7679.［16］王宇明，程林.慢性乙型肝炎抗病毒优化治疗策略的新认识［J］.中华肝脏病杂志，2012，20(2)：82-85.［17］中华医学会肝病学分会.中华医学会感染病学分会.慢性乙型肝炎防治指南［J］.中华肝脏病杂志，2011，19(1)：13-24.［18］Lu JJ，Liu K，Ma YJ，et al.Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil［J］.J Viral Hepat，2013，20(Suppl 1)：40-45.［19］刘国旺，唐克诚，李谦，等.替比夫定治疗慢性乙型重型肝炎疗效观察［J］.胃肠病学和肝病学杂志，2008，17(8)：662-664.［20］Wang L，Chen H，Fan C，et al.Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection［J］.J Med Virol，2013，85(11)：1907-1912.［21］He ZB，Wang JF，Liu KZ，et al.Randomized trial of lamivudine，adefovir，and the combination in HBeAg-positive chronic hepatitis B［J］.Clin Res Hepatol Gastroenterol，2012，36(6)：592-597.［22］耐药管理讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理［J］.实用肝脏病杂志，2013，16(1)：1-8.［23］Lok AS，Mcmahon BJ.Chronic hepatitis B：update 2009［J］.Hepatology，2009，50(3)：661-662.2014-03-18收稿 本文编辑：颜廷梅
